Follicular Lymphoma

The FDA announced several regulatory actions.

An infusion of lisocabtagene maraleucel induced deep and durable responses among most adults with relapsed or refractory follicular lymphoma, according to results of the phase 2 TRANSCEND FL trial.

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

CHICAGO – In this Healio video exclusive, Christopher Flowers, MD, discusses how the combination of zanubrutinib and obinutuzumab vs. obinutuzumab alone leads to longer PFS in patients with relapsed/refractory follicular lymphoma.

CHICAGO - In this video, Reid Merryman, MD, discusses updates on a trial testing the combination of epcoritamab, rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma.

More than 80% of a cohort of adults with relapsed or refractory follicular lymphoma exhibited an overall response to subcutaneously administered epcoritamab-bysp, according to topline data from the agent’s manufacturer.

Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.

NEW ORLEANS — Breakthrough COVID infection rates in patients with hematologic malignancies did not correlate with anti-spike antibody levels, suggesting mRNA vaccines may have lost efficacy against the omicron strain, according to a study.

The FDA granted accelerated approval to mosunetuzumab-axgb for treatment of adults with relapsed or refractory follicular lymphoma, the agency announced in a press release.

NEW ORLEANS — The addition of subcutaneous epcoritamab to rituximab and lenalidomide demonstrated encouraging efficacy as first-line treatment for follicular lymphoma, according to results presented at ASH Annual Meeting and Exposition.